We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+2.9%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.56B
AUM Growth
-$71.2M
Cap. Flow
-$99.6M
Cap. Flow %
-3.9%
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
27
Reduced
32
Closed
20

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$20M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.2M
3
AMGN icon
Amgen
AMGN
+$14.1M
4
PODD icon
Insulet
PODD
+$13.3M
5
BAX icon
Baxter International
BAX
+$11.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$31.7M
2
CI icon
Cigna
CI
+$22.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$22.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$13.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.28%
2 Real Estate 2.09%
3 Miscellaneous 1.37%
4 Industrials 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
126
Edgewise Therapeutics
EWTX
$4.74B
$1.17M 0.05%
150,418
-44,607
-23% -$376K
ZNTL icon
127
Zentalis Pharmaceuticals
ZNTL
$296M
$1.13M 0.04%
+40,156
New +$963K
BCYC
128
Bicycle Therapeutics
BCYC
$257M
$1.13M 0.04%
44,338
-44,338
-50% -$1.03M
GTHX
129
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.06M 0.04%
423,869
– –
FULC icon
130
Fulcrum Therapeutics
FULC
$288M
$848K 0.03%
256,888
+198,351
+339% +$583K
SRRK icon
131
Scholar Rock
SRRK
$6.09B
$821K 0.03%
108,833
– –
DHC
132
Diversified Healthcare Trust
DHC
$1.89B
$805K 0.03%
357,720
– –
THRX
133
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$700K 0.03%
75,000
– –
RCUS icon
134
Arcus Biosciences
RCUS
$3.1B
$667K 0.03%
32,839
– –
BDTX icon
135
Black Diamond Therapeutics
BDTX
$113M
$667K 0.03%
131,990
– –
ITOS
136
DELISTED
iTeos Therapeutics
ITOS
$606K 0.02%
45,735
– –
ICPT
137
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$576K 0.02%
52,067
– –
UHT
138
Universal Health Realty Income Trust
UHT
$566M
$536K 0.02%
11,258
– –
NHI icon
139
National Health Investors
NHI
$3.4B
$526K 0.02%
10,038
– –
BEAM icon
140
Beam Therapeutics
BEAM
$2.4B
$505K 0.02%
15,817
– –
TCRX icon
141
TScan Therapeutics
TCRX
$21.8M
$500K 0.02%
200,000
– –
ALXO icon
142
ALX Oncology
ALXO
$261M
$497K 0.02%
66,211
– –
CHCT
143
Community Healthcare Trust
CHCT
$420M
$492K 0.02%
14,900
– –
NBP
144
NovaBridge Biosciences American Depositary Shares
NBP
$184M
$486K 0.02%
162,580
– –
NVAX icon
145
Novavax
NVAX
$1.52B
$474K 0.02%
63,800
– –
HLVX
146
DELISTED
HilleVax
HLVX
$464K 0.02%
+27,000
New +$419K
STRO icon
147
Sutro Biopharma
STRO
$275M
$457K 0.02%
9,835
– –
CYH icon
148
Community Health Systems
CYH
$419M
$389K 0.02%
88,335
– –
AFMD
149
DELISTED
Affimed
AFMD
$351K 0.01%
58,604
– –
RPTX
150
DELISTED
Repare Therapeutics
RPTX
$308K 0.01%
29,150
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Tekla Capital Management held 186 positions worth $2.56B, down 2.7% from $2.63B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management withdrew a net $99.6M in Q2 2023, closing 20 positions and reducing 32 holdings. Its most notable exit was Travere Therapeutics, an estimated $9.41M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Miscellaneous.

Against the trend, Tekla Capital Management opened a new position in Insulet worth $12.6M.

  • Tekla Capital Management's largest Q2 2023 buy was Insulet: 43,847 shares worth $12.6M.
  • Tekla Capital Management added most to Merck in Q2 2023, an estimated $20M increase.
  • Tekla Capital Management's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $31.7M.
  • Tekla Capital Management fully exited Travere Therapeutics in Q2 2023, selling an estimated $9.41M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.56B portfolio in Q2 2023.
  • Tekla Capital Management opened 9 new positions and closed 20 in Q2 2023.
  • Tekla Capital Management's portfolio value fell 2.7% quarter-over-quarter to $2.56B.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.